Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008231 | 0.91 | CHRNA1 (0.50) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL7100026 | 0.82 | CHRNA1 (0.57) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL7006355 | 0.75 | CHRNA7 (0.68) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL7011069 | 0.72 | CHRNB2 (0.46) | CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL7009355 | 0.71 | HTR1D (0.47) | — | |
| SCHEMBL7011320 | 0.70 | ADRA2A (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL7128074 | 0.69 | LMNA (0.38) | ALDH1A1 | |
| SCHEMBL12986472 | 0.69 | CHRNA1 (0.84) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL7007927 | 0.67 | HTR1D (0.57) | — | |
| Iodide SCHEMBL7129576 | 0.66 | MEN1 (0.38) | CHRNA1CHRNB2CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100769-A1 | Cyclic amidine compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-05-29 | — | — | US | claimed |
| US-20030100769-A1 | Cyclic amidine compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-05-29 | — | — | US | disclosed |
| EP-1280793-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001081334-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100769-A1 | Cyclic amidine compounds | CHRM1, CHRM5, CCKAR | CHRNA1 16/4885CHRNB2 28/4885CHRNA3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.